All News

Steven Pipe, MD, explains the long-term efficacy data surrounding etranacogene dezaparvovec in patients with hemophilia B.

DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.

Amlenetug could provide a treatment option for patients with multiple system atrophy, a progressive and rare condition that causes damage to the brain’s nerve cells.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

RSV poses a significant threat to high-risk adults, but effective vaccines offer strong protection, highlighting the need for increased vaccination rates and education.

The indication is for symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

PP-01 could become a first-in-class treatment for patients with cannabis use disorder.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

Therapies like the newly approved suzetrigine, a nonopioid NaV1.8 pain signal inhibitor, could revolutionize pain management and mitigate the risks associated with opioid use.

Treatment with 2.4 mg of semaglutide did not increase the risk of developing suicidal ideation or behavior compared with placebo.

With a wealth of available nonprescription options, patients should know about various products and their uses.

Pharmacists can help patients and their caregivers manage seizures, assess seizure control, and recommend appropriate treatments such as phenobarbital or rescue medications.

Pharmacists can help educate patients, identify adverse events, and help patients communicate with other health care professionals or drug companies.

After gradually consuming increased doses of peanut butter, children who could initially tolerate about half a peanut could consume 3 tablespoons without an allergic reaction.

Through frequent interactions, pharmacists can discuss patients' treatment satisfaction, adherence issues, or potential adverse events.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

This surgery can be significant in reducing the long-term risk of adverse outcomes and decompensation in cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH).

Diabetes management through insulin could play a significant role in preventing antibiotic resistance.